AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00841243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrison (Nutricia)
Description: During 48 weeks of treatment, the patient will receive at T=0, 2, 4, 8, 12, 18, 24, 36, 48 weeks dietary advise combined with daily nutritional support in the form of a nutritional supplement drink at bedtime.
Study NCT04787731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Local Anesthetic
Description: Long lasting local anesthetic administered to be compared to Lidocaine for quality of life outcomes in dental patients undergoing endodontic treatment
Study NCT04071431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Result masking
Description: The quality control system randomly shows the RFQ result to the endoscopists and keep 50% of the RFQ results are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy.
Study NCT02263872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 200mg perday
Study NCT02263872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline
Description: Minocycline 200mg perday
Study NCT02691416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol postconditioning
Description: administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal
Study NCT02691416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: 0.5%-2% sevoflurane with BIS 40-60
Study NCT02569463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
Study NCT01736267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
Description: Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
Study NCT02989116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibition training
Description: Inhibition training on a tactile tablet for a month (20 sessions of 15 min)
Study NCT02989116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Description: Working memory training on a tactile tablet for a month (20 sessions of 15 min)
Study NCT02989116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Mindfulness training on a tactile tablet for a month (20 sessions of 15 min)
Study NCT02989116 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control training
Description: Active control training on a tactile tablet for a month (20 sessions of 15 min)
Study NCT02989116 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Saliva collection
Description: Collection of a saliva sample for genotyping
Study NCT02989116 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: Collection of a saliva sample for genotyping
Study NCT02989116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain Magnetic Resonance Imaging
Description: Structural and functional MRI
Study NCT02989116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Magnetic Resonance Imaging
Description: Structural and functional MRI
Study NCT02989116 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive testing
Description: Battery of cognitive and academic tasks on executive functions
Study NCT02989116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive testing
Description: Battery of cognitive and academic tasks on executive functions
Study NCT03627949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-intervention
Description: The intervention will address the basic elements of the HAPA model via the use of behaviour change techniques. In line with Abraham and Michie (2008), we use several behaviour change techniques like providing information about behavioural risk and benefit of behaviour change, prompting intention formation, prompting barrier identification, providing instructions how to perform a behaviour, prompting specific goal setting and review of behavioural goals, providing feedback on performance, prompting practice and providing follow-up prompts, prompting to plan social support and finally prompting relapse prevention, also based on strategies used by other effective computer tailoring programs. Students attended e-health intervention session once a week with about 20 minutes each time.
Study NCT02578160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inferior alveolar and lingual nerve block procedure
Description: inferior alveolar and lingual nerve block
Study NCT02578160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inferior alveolar and lingual nerve block procedure
Description: inferior alveolar and lingual nerve block
Study NCT00361972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole
Description: 30 mg of lansoprazole twice daily for 6 weeks
Study NCT00361972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
Study NCT01737762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HP802-247
Description: HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
Study NCT01737762 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT01606904 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy -based weight loss program
Description: CBT-based program includes 20 group visits
Study NCT01606904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy -based weight loss program
Description: CBT-based program includes 20 group visits
Study NCT01048398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
Study NCT01048398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Control group: intravenous paracetamol 1g
Study NCT03980782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Individualized music therapy developed playlist(s) that will be used based upon the latest Confusion Assessment Method result (hypoactive, hyperactive or no delirium) delivered twice daily.
Study NCT02194946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM therapies
Description: The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
Study NCT02194946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-related management
Description: Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
Study NCT02194946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-related management
Description: Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
Study NCT01021176 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spray
Description: 0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered
Study NCT01021176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: 0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
Study NCT00763256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan, Fluoride
Description: subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
Study NCT01372644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM 230 / Pasireotide
Study NCT00763256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
Study NCT01899131 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: platform-switch tapered internal implants
Description: Laser-Lok permanent abutment/ new Laser Lok platform-switch implant assembly.assessment at 6,12,24 month clinicaly and radiographic
Study NCT01877681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tele-assistance
Description: Assisted care (Tele-assistance) provided by an expert nurse through a informatic online application
Study NCT01877681 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Usual care as specified in the PU practice guideline
Study NCT01738685 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Intervention.
Study NCT00753961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fermented dairy product
Description: fermented dairy product (2 bottles/day during 16 weeks)
Study NCT00753961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non fermented dairy product
Description: non fermented dairy product (2 bottles/day during 16 weeks)
Study NCT01679522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-port laparoscopic surgical staging
Description: single-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
Study NCT01679522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four-port laparoscopic surgical staging
Description: Four-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
Study NCT02872324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procurement questionnaires
Study NCT04322240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid
Description: Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication
Study NCT04508062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pectopexy operation
Description: Vaginal cuff or uterine cervix will be attached to iliopectineal ligament with polypropylene mesh on both sides.
Study NCT04508062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterosacral ligaments plication operation.
Description: At least 2/3 of the sacrouterine ligaments will be shortened with helical sutures, starting from the cervix and so douglas will be partially obliterated.
Study NCT01975675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF 90/400 mg FDC tablet administered orally once daily
Study NCT04178070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 10mg
Description: 10mg (500μL), single dose, abdominal subcutaneous injection
Study NCT04178070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 15mg
Description: 15mg (750μL), single dose, abdominal subcutaneous injection
Study NCT04178070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 20mg
Description: 20mg (1mL), single dose, abdominal subcutaneous injection
Study NCT04178070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, 30mg
Description: 30mg (1.5mL), single dose, abdominal subcutaneous injection
Study NCT04178070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 30mg
Description: 30mg (1.5mL), single dose, abdominal subcutaneous injection
Study NCT01259115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
Study NCT01259115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole tablet
Description: Ketoconazole 200 mg tablets taken orally twice daily.
Study NCT01259115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ketoconazole tablet
Description: Placebo to match ketoconazole 200 mg tablets taken orally twice daily.
Study NCT02045992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine
Description: Five doses of 100mg of caffeine diluted in 100 ml of decaffeinated coffee. One dose every hour for five hours
Study NCT02245022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50mg od
Description: Patients randomised to receive either Dolutegravir 50mg od or standard of care (Efavirenz 600mg od) plus Lamivudine 300mg od/ Tenofovir 300mg od
Study NCT02245022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients are randomised 1:1 to receive either Dolutegravir 50mg once daily in combination with Lamivudine 300mg od and tenofovir 300mg od or standard of care (Efavirenz 600mg plus Lamivudine 300mg od and tenofovir 300mg od)
Study NCT03492827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine acetate gargle
Description: observe whether it can achieve the effect of preventing postoperative infection
Study NCT01196676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4451
Description: 1 mg capsules, 5 mg capsules, and 25 mg capsules
Study NCT01975675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
Study NCT03530618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible tip straight guidewire
Description: Use a flexible tip straight guidewire for ultrasound-guided central venous catheterization
Study NCT03530618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-tip
Description: Use a J tip straight guidewire for ultrasound-guided central venous catheterization
Study NCT02859987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PICC Placement by Landmark Technique
Description: Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
Study NCT02859987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PICC Placement by Ultrasound-guided Technique
Description: Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
Study NCT02859987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Scan
Description: Initially the nurses use ultrasound for explore venous anatomy and then they use real-time ultrasound imaging during needle placement
Study NCT04020276 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments. Each fraction will be escalated or de-escalated to meet the overall constraints in phase IA or both previously identified constraints in phase IB
Study NCT02915068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHR-Physician Asthma Care Education Program
Description: participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
Study NCT01141218 — intervention group
Intervention type: OTHER
Intervention: internet-based protocol and physician referral
Description: collection and review, dna and lab biomarker analysis, gene mapping
Study NCT01619592 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: webbased education (telemonitoring)
Description: Patients will be able to transmit their blood glucose values via the Internet to the diabetes professional and they will receive timely feedback. Timely will be defined as 'as agreed between the patient and the diabetes professional', e.g. every week on Friday afternoon.
Study NCT01196676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mg capsules, 5 mg capsules, and 25 mg capsules
Study NCT02518919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Child life intervention
Description: The participants will receive IV ketamine for sedation. In addition in this arm, 'Child Life Intervention', comfort measures provided by a trained child life therapist during painful procedures.
Study NCT02518919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening
Description: The participants will receive IV ketamine for sedation. In addition in this arm, 'Music Listening' to music chosen by the patient using headphones
Study NCT03023176 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone® standard IIV3
Description: Influenza Virus Vaccine Suspension (0.5ml) for Intramuscular Injection
Study NCT03023176 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone® standard IIV3 Pediatric Dose
Description: Influenza Virus Vaccine Suspension (0.25ml) for Intramuscular Injection
Study NCT04094376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: receiving operation during the day or at night
Description: eighty-four patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and the Night Group (18:00-22:00)
Study NCT04121754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-001
Description: Participants will walk using the investigational device (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 3 times a week for 5 weeks.
Study NCT04121754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Walking
Description: Participants will walk for thirty (30) minutes at a time, 3 times a week for 5 weeks. No mobile devices, music players or headphones will be allowed. They will wear foot sensors during their active walking sessions to measure gait biomechanics.
Study NCT03154177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group ANC/PNC
Description: The primary intervention is group antenatal and postnatal care wherein women receive their care in a group with other women with similar due dates. After an initial individual visit all care is given in groups although the majority of the time is dedicated to facilitated discussion and women can come for additional acute care if needed. Group antenatal care will be three group visits between 20 and 40 weeks gestation and group postnatal care will be one group visit and approximately 6 weeks post delivery.
Study NCT01593696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)
Description: Cells extracted, followed by induction chemotherapy before Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) infusion (dose escalation.)
Study NCT01331226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone counseling 3 sessions
Description: 3 sessions of telephone counseling
Study NCT03154177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound+Pregnancy Testing
Description: Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.~The primary analysis will not assess the effectiveness of this intervention.
Study NCT03154177 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound+Pregnancy Testing
Description: Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.~The primary analysis will not assess the effectiveness of this intervention.
Study NCT00976729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg
Study NCT00976729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: single SC doses, at safe and tolerable dose level
Study NCT00976729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo